Significantly lower pulmonary artery pressure in patients with nitric oxide therapy phase 2 trial results are positive

A few days ago, Bellerophon Therapeutics announced that a dose-escalation phase 2 clinical trial of inhaled nitric oxide therapy INOpulse has achieved positive results

Bellerophon's candidate cardiopulmonary product INOpulse is a combination drug-device therapy in which the active substance is nitric oxide

The other key results of the Phase 2 proof-of-concept test are as follows:

The iNO45 dose level (45μg/kg IBW/hr) reduced the patient’s median PVR by 20% (-54%~+22%) from the baseline (329 dyne/cm.

Increasing to the highest dose level iNO125 (125μg/kg IBW/hr) showed further improvement in PVR, with a median decrease of 29% (-43%~-5%), which was compared with the baseline (p=0.

With the improvement of PVR, the median mPAP of the iNO30 to iNO125 dose level group was reduced by 6-10% compared with the baseline (37.

During the acute hemodynamic dose escalation phase of the trial, no adverse events (TEAE) or serious adverse events (TESAE) occurred after treatment

Reference materials:

[1] Bellerophon Reports Positive Top-Line Data from Phase 2 Acute Dose Escalation Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Sarcoidosis.

(The original text has been deleted)